X0508 4 2025-03-04 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001726096 Daniell Richard C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL false true false false Exec. VP, European Commercial true Ordinary Shares 2025-03-04 4 M false 33512 A 33512 D Ordinary Shares 2025-03-04 4 S false 21870 15.7346 D 11641 D Ordinary Shares 2025-03-05 4 S false 11641 15.9132 D 0 D Ordinary Shares 2025-03-04 4 M false 20461 A 20461 D Ordinary Shares 2025-03-04 4 S false 13353 15.7346 D 7108 D Ordinary Shares 2025-03-05 4 S false 7108 15.9132 D 0 D Ordinary Shares 2025-03-04 4 M false 183169 A 183169 D Ordinary Shares 2025-03-04 4 S false 56385 15.7346 D 126784 D Ordinary Shares 2025-03-05 4 S false 30015 15.9132 D 96769 D Restricted Share Units 2025-03-04 4 M false 33512 0 D Ordinary Shares 33512 33512 D Restricted Share Units 2025-03-04 4 M false 20461 0 D Ordinary Shares 20461 61384 D Restricted Share Units 2025-03-04 4 M false 183169 0 D Ordinary Shares 183169 0 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026. Restricted share units were granted on March 4, 2024, with 20,461 vested on March 4, 2025, 20,461 vesting on each of March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025. /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 2025-03-06